US FDA reopens opportunity to comment on reprocessing of reusable medical device
This article was originally published in Clinica
The US Food and Drug Administration is giving stakeholders another chance to submit comments on factors affecting the reprocessing of reusable medical devices.
You may also be interested in...
Now that the European Medicines Agency has finalized its formal safety review procedure into Xeljanz, Pfizer is telling health care professionals what precautions they must take when prescribing the drug.
Health technology assessment body NICE is consulting on draft guidance that recommends Axonics' device for overactive bladder.